[ Price : $8.95]
Federal Register Notice: The Science Board to FDA will meet 9/15 to hear a report from the Science Looking Forward subcommittee.[ Price : $8.95]
Federal Register Notice: FDA corrects an 8/3 Federal Register Notice on a public workshop on surrogate endpoints for clinical tria...[ Price : $8.95]
Federal Register Notice: FDA publishes notice that an applicant for a proposed biosimilar product notified the agency that a paten...[ Price : $8.95]
Federal Register Notice: FDA approves a Sanofi-Aventis NDA for Praluent, for which the applicant redeemed a rare pediatric disease...[ Price : $8.95]
FDA approves a Novartis supplemental NDA for Promacta (eltrombopag) to treat low blood platelet count in pediatric patients ages ...[ Price : $8.95]
FDA extends by a few weeks its review of an Alkermes NDA for Aristada (aripiprazole lauroxil) for treating schizophrenia.[ Price : $8.95]
FDA grants Exelixis, Inc. a breakthrough therapy designation for cabozantinib and its use in treating patients with advanced renal...[ Price : $8.95]
The Federal Trade Commission recommends that FDA reconsider the framework it uses to regulate homeopathic medications because it m...